Patel Sanjiv, PRES, reported a transaction classified as grant at Relay Therapeutics, Inc. involving 994.000000 shares for an estimated $2972.06. Reported holdings after the transaction were 704209.000000 shares. A 10b5-1 reference was not detected in the stored filing text.
Stored Form 4 columns with their raw values
Badges describe filing facts only — not predictions.
Compact filing score computed from stored Form 4 facts. Version v1.
This filing has a meaningfully negative filing-only score. It is likely less useful as a positive insider-activity signal.
Form 4 relationship flags and nearby filing context
President and CEO
The shares were acquired under the Relay Therapeutics, Inc. 2020 Employee Stock Purchase Plan ("ESPP") in a transaction that was exempt under both Rule 16b-3(d) and Rule 16b-3(c). The reporting person…
In accordance with the ESPP, these shares were purchased at a price equal to 85% of the closing price of the Issuer's common stock on July 1, 2025.
Includes 136,854 shares underlying restricted stock units ("RSUs").
Sale of shares to cover the reporting person's income tax withholding obligations upon the vesting of 136,854 shares of RSUs on January 5, 2026. The reporting person had no discretion with respect to…
These shares are held in irrevocable trusts for the benefit of the reporting person's family members. An independent trustee is trustee of the trusts. The reporting person disclaims beneficial ownersh…
These shares were held in irrevocable trusts for the benefit of the reporting person's family members. An independent trustee is trustee of the trusts. The reporting person disclaims beneficial owners…
0 other filings
0 recent txs